To successfully launch rare disease drugs, with their small patient populations and high costs, pharma manufacturers need to get payers involved in discussions as soon as possible to ensure patient access.
Tag Archive for: Payers
Accelerated approval allows the FDA to rely on surrogate or intermediate clinical endpoints to approve therapies in a shorter time frame than would be possible with traditional endpoints, but it has come under scrutiny by some policymakers and researchers in recent years.
“In a rapidly changing healthcare landscape, new policies combined with significant cost pressures and evolving business models continue to impact drug access and potentially increase restrictions,” said Kim Wishnow-Per, President, MHMM. “We created these proprietary solutions following conversations with our client partners and listening to their specific needs. By designing these three offerings to help solve for their challenges, we are excited to bring new value to our clients and their customers.”
“We want to introduce Precision AQ as a team of advisors, experts, and creators to sit in the room with our clients to partner, looking at access as a continuum,” President Doug Fulling told Med Ad News. “This has been 10 years in the making. We started the rebrand process six months ago, but the reason that we’re doing this now is we want to simplify our North Star and where we’re going in the marketplace.”
Recent U.S. policy changes and the introduction of the Inflation Reduction Act (IRA) have injected a sense of urgency within pharma companies for greater cross functional cooperation. The traditional route that drugs take through the development process from bench to patient needs a radical rethink. Any pressure on how drugs are assessed through the AA route will further ramp up the urgency within pharma to align internally.
Market access emerged as a crucial commercial function at pharmaceutical manufacturers a little over 20 years ago, followed closely by the creation of specialized market access agencies. With so much changing over the last two decades, the time is right to take a fresh look at how market access agencies support manufacturers today to ensure that expectations are aligned and that unrealized potential doesn’t negatively impact brands.
How pharma companies can communicate effectively in today’s evolving marketplace and why it is the right time to embrace our humanity when engaging various stakeholders along the product, patient, and reimbursement/coverage journeys.
Part V: Cost pressures, increasing value while improving health outcomes, and leveraging real-world evidence are top of mind.
This first-to-market technology gives patient service teams nearly immediate insight into patient coverage from both pharmacy and major medical plans, the potential need for prior authorization support, and any financial responsibilities impacting patient access and speed to treatment.
the Digital Medicine Society (DiMe) released findings from a digital health industry needs assessment to identify 1) the drivers of successful digital health product development and adoption, and 2) the regulatory policy needed to facilitate these drivers.